Cargando…
Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
Globally, hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates. Unfortunately, many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate. Before 2008, no effective drug treatments...
Autores principales: | Alqahtani, Saleh A, Colombo, Massimo G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713315/ https://www.ncbi.nlm.nih.gov/pubmed/35070040 http://dx.doi.org/10.4251/wjgo.v13.i12.2038 |
Ejemplares similares
-
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
por: Kanat, Ozkan, et al.
Publicado: (2019) -
Systemic treatment for unresectable hepatocellular carcinoma
por: Leowattana, Wattana, et al.
Publicado: (2023) -
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
por: Jain, Ankit, et al.
Publicado: (2021) -
Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021) -
Evolution and current status of the subclassification of intermediate hepatocellular carcinoma
por: Yi, Peng-Sheng, et al.
Publicado: (2020)